<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741685</url>
  </required_header>
  <id_info>
    <org_study_id>C-380</org_study_id>
    <nct_id>NCT04741685</nct_id>
  </id_info>
  <brief_title>Clinical Efectivity of Two Different Sensor-augmented Pumps With Low Predictive Suspension Function</brief_title>
  <official_title>Clinical Efectivity of Two Different Sensor-augmented Pumps With Low Predictive Suspension Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Castilla-La Mancha Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Castilla-La Mancha Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational cross-sectional multicenter study about effectiveness of two different sensor&#xD;
      augmented-pumps with low glucose predictive function in Type 1 Diabetes Mellitus (T1DM) adult&#xD;
      patients in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cross-sectional multicenter analysis about clinical effectiveness of two different&#xD;
      sensor-augmented pumps, Tandem T Slim X2 with Basal IQ (TTSX2) and Medtronic Minimed 640G&#xD;
      with Smartguard (MM640G) in adult patients with type 1 Diabetes mellitus.&#xD;
&#xD;
      All clinical variables are gathered from three EMR softwares and two sensor-augmented pumps&#xD;
      sotwares.&#xD;
&#xD;
      Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are&#xD;
      presented as mean ± SD values or percentages. A Kruskal-Wallis or a Friedman test were used&#xD;
      for the analysis of differences. Comparisons between proportions were analyzed using a&#xD;
      chi-squared test. A &quot;P&quot; value &lt; 0.05 was considered statistically significant.&#xD;
&#xD;
      The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic&#xD;
      Committee. All participants provided written informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>TIR</measure>
    <time_frame>during the procedure</time_frame>
    <description>time in range (TIR, 70-180 mg/dL, 3.9-10 mmol/L) of the interstitial glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TBR</measure>
    <time_frame>during the procedure</time_frame>
    <description>time below range (TBR, &lt;70 mg/dL, &lt;3.9 mmol/L) of the interstitial glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAR</measure>
    <time_frame>during the procedure</time_frame>
    <description>time above range (TIR, 70-180 mg/dL, 3.9-10 mmol/L) of the interstitial glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>during the procedure</time_frame>
    <description>Glycate haemoglobina A1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMI</measure>
    <time_frame>during the procedure</time_frame>
    <description>Glucose management index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAGE</measure>
    <time_frame>during the procedure</time_frame>
    <description>Mean amplitude glucose excursions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%CV</measure>
    <time_frame>14 days</time_frame>
    <description>Coefficient of variation percentage of the intersticial glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DQOL</measure>
    <time_frame>during the procedure</time_frame>
    <description>Diabetes quality of life (EsDQOL questionnary score), 43 questions, each question with a score from 1 to 5, worse score is five points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia perception 1</measure>
    <time_frame>during the procedure</time_frame>
    <description>Hypoglycemia unawareness (Clarke questionnary score), 8 questions, each one score &quot;R&quot; or &quot;not R&quot;, more &quot;R&quot; means worse score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia perception 2</measure>
    <time_frame>during the procedure</time_frame>
    <description>Hypoglycemia unawareness (Gold questionnary scores), single question, score from 0 to 5, worse score is five points.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>SAP with LGS</arm_group_label>
    <description>Type 1 diabetes adults patients treated with sensor-augmented insulin pump with low glucose predictive suspension function</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TTSX2</intervention_name>
    <description>Treatment with Tandem T Slim X2 with Basal IQ</description>
    <arm_group_label>SAP with LGS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MM640G</intervention_name>
    <description>Treatment with Medtronic Minimed 640G with Smartguard</description>
    <arm_group_label>SAP with LGS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 1 diabetes adult patients treated with sensor-augmented pump (TTSX2 or MM640G)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Treated with TTSX2 or MM640.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other kind of diabetes.&#xD;
&#xD;
          -  Serious mental disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nuestra Señora de la Candelaria University Hospital</name>
      <address>
        <city>Tenerife</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Badajoz University Hospital</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obispo Rafael Torija, St.</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Castilla-La Mancha Health Service</investigator_affiliation>
    <investigator_full_name>Jesús Moreno Fernández</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>All clinical data if requested.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

